Holen Sie sich die Stockscreener-App
1.28
3.23%
0.04
Schlusskurs vom Vortag:
$1.24
Offen:
$1.24
24-Stunden-Volumen:
1.01M
Relative Volume:
0.95
Marktkapitalisierung:
$83.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-192.96M
KGV:
-0.3879
EPS:
-3.3
Netto-Cashflow:
$-167.04M
1W Leistung:
+8.47%
1M Leistung:
+5.79%
6M Leistung:
-46.44%
1J Leistung:
-66.62%
1-Tages-Spanne:
$1.225
$1.32
1-Wochen-Bereich:
$1.14
$1.32
52-Wochen-Spanne:
$0.783
$5.66
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Firmenname
Ventyx Biosciences Inc
Sektor
Branche
Telefon
(858) 945-2393
Adresse
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Vergleichen Sie VTYX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
1.28 | 83.97M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.50 | 126.09B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.91 | 64.01B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
629.51 | 36.63B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
257.19 | 30.64B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.77 | 27.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-03-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-11-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-07 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2023-11-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-19 | Eingeleitet | Goldman | Buy |
| 2022-11-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-07 | Eingeleitet | Stifel | Buy |
| 2022-09-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-09 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-02-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-15 | Eingeleitet | Jefferies | Buy |
| 2021-11-15 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Ventyx Biosciences Inc Aktie (VTYX) Neueste Nachrichten
Geode Capital Management LLC Increases Stock Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Renaissance Technologies LLC Acquires 310,800 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Stock Market Recap: Ventyx Biosciences Inc (VTYX) Concludes at 1.15, a -4.96 Surge/Decline - DWinneX
Ventyx Biosciences Inc’s Market Journey: Closing Strong at 1.43, Up 0.70 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
The Psychology of Ventyx Biosciences Inc Inc. (VTYX) Price Performance: Understanding Market Sentiment - investchronicle.com
JPMorgan Chase & Co. Trims Stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
VTYX FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class ActionVTYX - The Globe and Mail
Trading Day Review: Ventyx Biosciences Inc (VTYX) Loses Momentum, Closing at 1.16 - DWinneX
Ventyx Biosciences Inc [NASDAQ: VTYX] Sees Decrease in Stock Value - knoxdaily.com
Ventyx Biosciences Inc (VTYX) stock analysis: A comprehensive overview - uspostnews.com
Arthralgia Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis - The Globe and Mail
VENTYX INVESTOR UPDATE: Ventyx’s (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details - ACCESS Newswire
Investors who lost money on Ventyx Biosciences, Inc.(VTYX) should contact Levi & Korsinsky about pending Class ActionVTYX - ACCESS Newswire
Is the Ventyx Biosciences Inc (NASDAQ:VTYX) stock an investment opportunity? - uspostnews.com
Ventyx Biosciences stock hits 52-week low at $0.89 amid market challenges - Investing.com Australia
Ventyx Biosciences stock hits 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa
Is Ventyx Biosciences Inc (NASDAQ: VTYX) Still Trending? - stocksregister.com
Ventyx Biosciences chief scientific officer John Nuss sells $2,019 in shares - Investing.com India
VTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
Shareholders that lost money on Ventyx Biosciences, Inc.(VTYX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire
Stock Traders Purchase Large Volume of Call Options on Ventyx Biosciences (NASDAQ:VTYX) - Defense World
Ventyx boosts advisory board with top scientists By Investing.com - Investing.com South Africa
Ventyx boosts advisory board with top scientists - Investing.com
Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts - GlobeNewswire
7 World-Class NLRP3 Experts Join Ventyx as Phase 2 Trials Advance in Parkinson's Disease - Stock Titan
Insiders' US$1.26m Investments In Red Following Ventyx Biosciences' US$11m Dip In Market Value - simplywall.st
Ventyx Biosciences stock hits 52-week low at $1.21 amid market challenges - Investing.com
VTYX Stock Sees Decline of Approximately -9.63% in Last Five Days - knoxdaily.com
Ventyx Biosciences stock hits 52-week low at $1.28 amid market challenges - Investing.com Australia
Ventyx Biosciences Faces Supply Chain Risks Amidst U.S.-China Tensions and Regulatory Challenges - MSN
Ventyx Biosciences stock hits 52-week low at $1.37 amid market challenges - Investing.com Australia
Rhumbline Advisers Acquires 40,813 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights – VTYX - ACCESS Newswire
Ventyx Biosciences Reports 2024 Financial Results and Progress - TipRanks
Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc.(VTYX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Ventyx Biosciences stock hits 52-week low at $1.41 amid market challenges - Investing.com India
Ventyx Biosciences stock hits 52-week low at $1.41 amid market challenges By Investing.com - Investing.com South Africa
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Finanzdaten der Ventyx Biosciences Inc-Aktie (VTYX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
2.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):